Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the benefits of the South Korean health authorities decision to increase the range of medical conditions for which they will reimburse the cost of using ODM. Ewan explains what this means for Deltex, other international markets and his thoughts on how 2017 will play out.
Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies. The company’s ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
